Enhanced apoptosis and mitochondrial cell death by paclitaxel-loaded TPP-TPGS 1000 -functionalized nanoemulsion.
Pavan K YadavPooja YadavAmrendra K TiwariSaurabh VermaRafquat RanaDivya ChauhanKeerti MishraAshwini S KedarNavodayam KalletiJiaur R GayenWahajuddin MuhammadSrikanta K RathMadhav N MugaleKalyan MitraDeepak SharmaManish Kumar ChourasiaPublished in: Nanomedicine (London, England) (2023)
Background: The present research was designed to develop a nanoemulsion (NE) of triphenylphosphine-D-α-tocopheryl-polyethylene glycol succinate (TPP-TPGS 1000 ) and paclitaxel (PTX) to effectively deliver PTX to improve breast cancer therapy. Materials & methods: A quality-by-design approach was applied for optimization and in vitro and in vivo characterization were performed. Results: The TPP-TPGS 1000 -PTX-NE enhanced cellular uptake, mitochondrial membrane depolarization and G 2 M cell cycle arrest compared with free-PTX treatment. In addition, pharmacokinetics, biodistribution and in vivo live imaging studies in tumor-bearing mice showed that TPP-TPGS 1000 -PTX-NE had superior performance compared with free-PTX treatment. Histological and survival investigations ascertained the nontoxicity of the nanoformulation, suggesting new opportunities and potential to treat breast cancer. Conclusion: TPP-TPGS 1000 -PTX-NE improved the efficacy of breast cancer treatment by enhancing its effectiveness and decreasing drug toxicity.
Keyphrases
- cell death
- cell cycle arrest
- oxidative stress
- cancer therapy
- drug delivery
- pi k akt
- randomized controlled trial
- high resolution
- systematic review
- metabolic syndrome
- type diabetes
- computed tomography
- adverse drug
- replacement therapy
- insulin resistance
- smoking cessation
- human health
- free survival
- wound healing
- photodynamic therapy